The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $0.74 in the prior trading day, Aptevo Therapeutics Inc (NASDAQ: APVO) closed at $0.68, down -7.28%. In other words, the price has decreased by -$7.28 from its previous closing price. On the day, 0.57 million shares were traded. APVO stock price reached its highest trading level at $0.749 during the session, while it also had its lowest trading level at $0.68.
Ratios:
Our goal is to gain a better understanding of APVO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.64 and its Current Ratio is at 2.64. In the meantime, Its Debt-to-Equity ratio is 0.44 whereas as Long-Term Debt/Eq ratio is at 0.44.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, APVO now has a Market Capitalization of 1182952 and an Enterprise Value of -10460857.
Stock Price History:
Over the past 52 weeks, APVO has reached a high of $91.96, while it has fallen to a 52-week low of $0.67. The 50-Day Moving Average of the stock is -84.72%, while the 200-Day Moving Average is calculated to be -95.08%.
Shares Statistics:
The stock has traded on average 263.32K shares per day over the past 3-months and 851550 shares per day over the last 10 days, according to various share statistics. A total of 1.61M shares are outstanding, with a floating share count of 1.60M. Insiders hold about 0.61% of the company’s shares, while institutions hold 2.75% stake in the company. Shares short for APVO as of 1711584000 were 34256 with a Short Ratio of 0.13, compared to 1709164800 on 3496. Therefore, it implies a Short% of Shares Outstanding of 34256 and a Short% of Float of 5.12.
Earnings Estimates
A comprehensive evaluation of Aptevo Therapeutics Inc (APVO) is underway, with the input of 2.0 analysts contributing to its current rating.On average, analysts expect EPS of -$12.84 for the current quarter, with a high estimate of -$11.59 and a low estimate of -$14.1, while EPS last year was $17.16. The consensus estimate for the next quarter is -$6.53, with high estimates of -$1.89 and low estimates of -$11.17.
Analysts are recommending an EPS of between -$8.85 and -$31.5 for the fiscal current year, implying an average EPS of -$20.17. EPS for the following year is -$8.07, with 2.0 analysts recommending between -$5.65 and -$10.5.
